Correlation Between Sonnet Biotherapeutics and LMF Acquisition

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Sonnet Biotherapeutics and LMF Acquisition at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sonnet Biotherapeutics and LMF Acquisition into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sonnet Biotherapeutics Holdings and LMF Acquisition Opportunities, you can compare the effects of market volatilities on Sonnet Biotherapeutics and LMF Acquisition and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sonnet Biotherapeutics with a short position of LMF Acquisition. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sonnet Biotherapeutics and LMF Acquisition.

Diversification Opportunities for Sonnet Biotherapeutics and LMF Acquisition

0.56
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Sonnet and LMF is 0.56. Overlapping area represents the amount of risk that can be diversified away by holding Sonnet Biotherapeutics Holding and LMF Acquisition Opportunities in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on LMF Acquisition Oppo and Sonnet Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sonnet Biotherapeutics Holdings are associated (or correlated) with LMF Acquisition. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of LMF Acquisition Oppo has no effect on the direction of Sonnet Biotherapeutics i.e., Sonnet Biotherapeutics and LMF Acquisition go up and down completely randomly.

Pair Corralation between Sonnet Biotherapeutics and LMF Acquisition

Given the investment horizon of 90 days Sonnet Biotherapeutics Holdings is expected to under-perform the LMF Acquisition. In addition to that, Sonnet Biotherapeutics is 1.19 times more volatile than LMF Acquisition Opportunities. It trades about -0.08 of its total potential returns per unit of risk. LMF Acquisition Opportunities is currently generating about -0.06 per unit of volatility. If you would invest  238.00  in LMF Acquisition Opportunities on December 1, 2024 and sell it today you would lose (65.00) from holding LMF Acquisition Opportunities or give up 27.31% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Sonnet Biotherapeutics Holding  vs.  LMF Acquisition Opportunities

 Performance 
       Timeline  
Sonnet Biotherapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Sonnet Biotherapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.
LMF Acquisition Oppo 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days LMF Acquisition Opportunities has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Sonnet Biotherapeutics and LMF Acquisition Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Sonnet Biotherapeutics and LMF Acquisition

The main advantage of trading using opposite Sonnet Biotherapeutics and LMF Acquisition positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sonnet Biotherapeutics position performs unexpectedly, LMF Acquisition can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in LMF Acquisition will offset losses from the drop in LMF Acquisition's long position.
The idea behind Sonnet Biotherapeutics Holdings and LMF Acquisition Opportunities pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.

Other Complementary Tools

ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope